A new french initiative aims to expand access to Boron Neutron Capture Therapy (BNCT), a highly targeted cancer treatment first developed in the 1950s [[1]]. The collaboration between the Institut du Cancer de Montpellier (ICM) and TAE Life Sciences seeks to establish BNCT capabilities in the Montpellier region, offering a potential new option for patients whose cancers have recurred after conventional treatment. Japan approved BNCT in 2020 [[2]], and this project marks a critically important step towards bringing the therapy – which utilizes a boron-containing drug and a neutron beam to destroy cancer cells [[3]] – to more patients in Europe.
A new collaboration aims to bring a cutting-edge cancer treatment, known as Boron Neutron Capture Therapy (BNCT), to France. This therapy offers a potential “second chance” for patients with cancers that have proven difficult to treat, highlighting the ongoing search for more effective oncology solutions.
The Institut du Cancer de Montpellier (ICM) and TAE Life Sciences recently signed an agreement to launch the AMBRE project – an alliance focused on establishing BNCT capabilities in the Montpellier region. According to Dr. David Azria, head of the Radiotherapy Oncology department at ICM and president of the French Society of Radiation Oncology, BNCT is a “care to cure” approach.
BNCT is an advanced form of targeted radiotherapy with the potential to significantly improve outcomes for patients with aggressive cancers. The therapy is particularly promising for challenging tumors including glioblastoma (a particularly aggressive form of brain cancer), pancreatic cancer, and cancers of the head and neck.
“These are cancers that have already been treated with conventional radiotherapy and have recurred,” Dr. Azria explained. BNCT works by delivering a boron-containing drug to the tumor, then using a neutron beam to activate the boron, selectively destroying the cancer cells while sparing surrounding healthy tissue. This targeted approach could offer new hope for patients with limited treatment options.
The development of BNCT in France represents a significant step forward in cancer care, potentially offering a new avenue for treatment and improved quality of life for patients facing difficult diagnoses.
